Saturday, November 2, 2024

CATEGORY

Bayer

Bayer and Liveo Research Launch Innovative Blister Packaging with Significant Environmental Benefits

Key TakeawaysSignificant reduction in carbon footprint and environmental impact. Improved sustainability without additional cost. Commitment to maintaining product quality and safety. Collaboration with...

Bayer and Dewpoint Therapeutics Forge Landmark Heart Disease Licensing Deal

Bayer has taken a significant step forward in the treatment of heart disease by securing an exclusive licensing agreement with Dewpoint Therapeutics. This collaboration,...

Bayer Joins Forces with Start-Up for Hormone Monitoring Breakthrough

In an ambitious move to push the boundaries of women's health, Bayer has secured a partnership with Impli, a start-up renowned for its cutting-edge...

Bayer and Orion Submit Darolutamide for Expanded Prostate Cancer Treatment in Europe

Key TakeawaysBayer, in collaboration with Orion, has submitted darolutamide for approval by the European Medicines Agency (EMA), aiming to expand its use in...

Bayer and MOMA Therapeutics Partner on Precision Oncology Small Molecule Program

Key TakeawaysBayer and MOMA Therapeutics enter a collaboration to develop a small molecule oncology program, enhancing Bayer’s precision oncology portfolio. MOMA will receive...

FDA Accepts Bayer’s New Drug Application for Elinzanetant to Treat Menopause and its Symptoms

Key TakeawaysBayer’s New Drug Application for elinzanetant, targeting moderate to severe vasomotor symptoms (VMS) in menopausal women, has been accepted by the U.S....

Positive 24-Month Data for BlueRock’s Bemdaneprocel in Parkinson’s Disease Trial

Key TakeawaysBlueRock’s bemdaneprocel continues to show a favorable safety profile at 24 months in the Phase 1 exPDite trial for Parkinson's disease. Early...

Bayer Seeks FDA Approval for Darolutamide in Metastatic Prostate Cancer

Key TakeawaysBayer submits an application for darolutamide in combination with ADT for metastatic hormone-sensitive prostate cancer (mHSPC). The Phase III ARANOTE trial showed...

NECA Confirms Intrauterine Device as a Safe and Effective Long-Term Contraceptive Option with Manageable Side Effects

Key TakeawaysThe intrauterine device, including Mirena, offers long-term contraception with a failure rate of less than 1%, lasting between three to five years,...

mHSPC: Darolutamide Plus ADT Shows Significant Reduction in Radiological Progression or Death

Key TakeawaysDarolutamide plus ADT reduced the risk by 46% in mHSPC patients compared to placebo plus ADT. The safety of darolutamide was consistent...

Safety Profile Highlighted in New Eyleaâ„¢ 8 mg Data from EURETINA 2024

Key TakeawaysA post-hoc analysis from the PULSAR trial revealed that Eyleaâ„¢ 8 mg provided rapid and sustained control of retinal fluid, particularly when...

Menopause Study Shows Promising Results for Elinzanetant in Treating Moderate to Severe Symptoms

Key TakeawaysThe Phase III OASIS 3 study demonstrated a statistically significant reduction in vasomotor symptoms (VMS) in women treated with elinzanetant, adding to...

Oncology Advances: Bayer to Present Extensive New Data from Its Oncology Portfolio at ESMO 2024

Key TakeawaysBayer will present late-breaking data from its oncology portfolio, including results from the Phase III ARANOTE trial on darolutamide in metastatic hormone-sensitive...

Finerenone Shows Significant Cardiovascular Benefits in Heart Failure Patients with Preserved Ejection Fraction

Key TakeawaysFinerenone significantly improves cardiovascular outcomes in heart failure patients with mildly reduced or preserved ejection fraction, reducing the risk of cardiovascular death...

Heart Failure Management Advances as Bayer Showcases Late-Breaking Phase III Data from FINEARTS-HF Study with Finerenone

Kay TakeawaysBayer's FINEARTS-HF study highlights the potential of finerenone in improving heart failure management for patients with mildly reduced or preserved ejection fraction,...

Latest news